Follow Our Live Coverage of COVID-19 Developments

Reclast Approved as Once-Yearly Osteoporosis Drug

For postmenopausal women

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Aug. 20, 2007 (HealthDay News) -- The Novartis drug Reclast (zoledronic acid) has been approved by the U.S. Food and Drug Administration as a once-yearly treatment for postmenopausal osteoporosis, the company said Monday.

In a clinical study involving more than 7,700 women, Reclast reduced the risk of spine fracture by 70 percent and hip fracture by 41 percent, the company said in a statement. The drug is administered as a 15-minute intravenous injection.

The most common side effects reported were pain in the muscles, joints, or bones; flu-like symptoms, and headache.

Osteoporotic fractures lead to about 800,000 emergency room visits, 500,000 hospitalizations, 180,000 nursing home placements, and 2.6 million doctor visits each year, costing up $17.9 billion annually, Novartis said.

In April, Reclast was approved to treat another bone disorder, Paget's disease, which affects about 1 million people in the United States.

More information

Visit this FDA page to learn more about osteoporosis.


Last Updated: